LQDA - Liquidia Technologies, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.52
-0.63 (-8.81%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.00
Open7.28
Bid6.52 x 4000
Ask7.32 x 900
Day's Range6.32 - 7.75
52 Week Range2.65 - 20.05
Volume108,156
Avg. Volume185,785
Market Cap168.356M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.47
Earnings DateFeb 23, 2020 - Feb 27, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.25
  • GlobeNewswire

    Liquidia Announces Poster Presentation at the 14th Annual World Congress of the Pulmonary Vascular Research Institute (PVRI)

    LIQ861 is an inhaled dry powder formulation of treprostinil designed using Liquidia’s PRINT® technology to enhance deep-lung delivery using a convenient, palm-sized dry powder inhaler (“DPI”) for the treatment of pulmonary arterial hypertension (PAH). Liquidia believes LIQ861 can overcome the limitations of current inhaled therapies and has the potential to maximize the therapeutic benefits of treprostinil in treating PAH by safely delivering higher doses into the lungs.

  • Will Liquidia Continue to Surge Higher?
    Zacks

    Will Liquidia Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Liquidia.

  • Liquidia nets $22.4 million as it moves forward with lead drug
    American City Business Journals

    Liquidia nets $22.4 million as it moves forward with lead drug

    Ahead of a planned regulatory application early next year, a Triangle drugmaker has brought in more than $22 million.

  • MarketWatch

    Liquidia Technologies stock soars after Wedbush says private placement gives company runway through Q4 2020

    Shares of Liquidia Technologies Inc. , a Durham, N.C.-based biotech, soared more than 70% Thursday before paring their gains, after Wedbush reiterated an outperform rating on the stock and said a $22.4 million fundraising will give the company the runway to keep going through the fourth quarter of 2020. The company said it sold 7.2 million shares at $3.13 a share in a private placement. Liquidia is aiming to leverage its proprietary Print technology to improve the clinical profile of approved active pharmaceutical ingredients, or APIs. The company's lead candidate called LIQ861 is a dry powder formulation of inhaled treprostinil to treat pulmonary arterial hypertension, or PAH. "In our view, LIQ861 has the potential to improve the therapeutic profile of treprostinil in treating PAH by safely delivering higher doses into the lung," Wedbush analysts led by Liana Moussatos wrote in a note to clients. The company is expecting to file a new drug application for the treatment in the first quarter of 2020. A second product candidate, LIQ865, a treatment for post-operative pain, is expected to enter phase 2 trials in 2020, said the note. Shares were last up 43% and have fallen 77% in the year to date, while the S&P 500 has gained 29%. Company plans to initiate a Phase 2 study in 2020.

  • GlobeNewswire

    Liquidia Technologies Announces $22.4 Million Private Placement

    The private placement is expected to close on or about December 27, 2019, subject to the satisfaction of customary closing conditions. Jefferies acted as the sole placement agent to Liquidia in connection with the private placement.

  • Is Liquidia Technologies, Inc. (LQDA) A Good Stock To Buy?
    Insider Monkey

    Is Liquidia Technologies, Inc. (LQDA) A Good Stock To Buy?

    As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the third quarter. We get to see hedge funds' thoughts towards the market and […]

  • Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates

    Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -38.46% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Liquidia Technologies Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    Completed Registrational Studies of LIQ861 to Include in New Drug Application (NDA)Targeting Submission of NDA for LIQ861 in 1Q 2020Management to Host Webcast and Conference.

  • ACCESSWIRE

    Liquidia Technologies, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 13, 2019 / Liquidia Technologies, Inc. (NASDAQ: LQDA ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on November 13, 2019 ...

  • GlobeNewswire

    Liquidia to Report Third Quarter 2019 Financial Results and Provide Corporate Update on November 13, 2019

    RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2019 -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today.

  • GlobeNewswire

    Liquidia Technologies Appoints Industry Veteran Katie Rielly-Gauvin to Board of Directors

    Liquidia Technologies, Inc. (LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced the appointment of Katie Rielly-Gauvin, Vice President of Global Commercial Development at AbbVie, to the Company’s Board of Directors (the “Board”) as a Class II director with a term expiring at the 2020  annual meeting of stockholders and to the Company’s Research and Development Committee and Nominating & Governance Committee. “Adding Katie to our Board is another significant step in preparing Liquidia for commercial growth,” said Stephen Bloch, M.D., Chairman of the Board.

  • Liquidia Technologies, Inc. (LQDA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
    Zacks

    Liquidia Technologies, Inc. (LQDA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

    Liquidia Technologies, Inc. (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Is Liquidia Technologies (NASDAQ:LQDA) Using Too Much Debt?
    Simply Wall St.

    Is Liquidia Technologies (NASDAQ:LQDA) Using Too Much Debt?

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • GlobeNewswire

    Liquidia to Present at Cantor 2019 Global Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Sept. 25, 2019 -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company,.

  • GlobeNewswire

    Liquidia Technologies Appoints Industry Veteran Dr. Joanna Horobin to Board of Directors

    “Joanna is an excellent addition to Liquidia’s Board as she is an industry veteran in drug development and commercialization across several therapeutic areas,” said Stephen Bloch, M.D., Chairman of the Board.

  • GlobeNewswire

    Liquidia to Present at H.C. Wainwright Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company,.

  • GlobeNewswire

    Liquidia to Present at Wedbush PacGrow Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2019 -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company,.

  • GlobeNewswire

    Liquidia Technologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    On Track for Planned New Drug Application (NDA) Submission for LIQ861 in Late 2019 Continued Pipeline Progress Leveraging Proprietary PRINT® Technology Management to Host.

  • GlobeNewswire

    Liquidia to Report Second Quarter 2019 Financial Results and Provide Corporate Update on August 8, 2019

    RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2019 -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the.

  • Could Liquidia Technologies, Inc.'s (NASDAQ:LQDA) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Liquidia Technologies, Inc.'s (NASDAQ:LQDA) Investor Composition Influence The Stock Price?

    Every investor in Liquidia Technologies, Inc. (NASDAQ:LQDA) should be aware of the most powerful shareholder groups...

  • Hedge Funds Have Never Been This Bullish On Liquidia Technologies, Inc. (LQDA)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Liquidia Technologies, Inc. (LQDA)

    Is Liquidia Technologies, Inc. (NASDAQ:LQDA) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]

  • GlobeNewswire

    Liquidia and GSK Restructure Collaboration Agreement

    Liquidia Technologies, Inc. (LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology, today announced that it has amended its collaboration agreement with GlaxoSmithKline (GSK) for the development and commercialization of pharmaceuticals based upon the Company’s proprietary PRINT® technology delivered through the inhalation route of administration. The amended collaboration agreement provides the Company with the right to develop and commercialize three additional PRINT®-based therapeutics delivered via inhalation. Additionally, under the amended collaboration agreement, the Company can acquire rights to pursue additional PRINT®-based programs for inhalation therapy, subject to GSK’s approval.

  • GlobeNewswire

    Liquidia Announces Clinical Update on INSPIRE; Targeting NDA Filing for LIQ861 in Late 2019

    Results from the INSPIRE study indicates that the 75 mcg capsule strength of LIQ861 (single capsule, 1-2 breaths) correlates with the 54 mcg dose of Tyvaso® (9 breaths), the maximum recommended label dose of Tyvaso®. INSPIRE also included a one-directional, crossover sub-study to assess the comparable bioavailability and pharmacokinetics (PK) of single doses of LIQ861 and Tyvaso in 18 PAH patients. The company targets NDA submission in late 2019 that will include additional data generated from ongoing development activities.